Recombinant AAV Delivery to the Central Nervous System

Methods in Molecular Biology

Volumn 807, Issue , 2011, Pages 159-177

  Bockstael, Olivier ^a   Foust, Kevin D ^b   Kaspar, Brian ^b   Tenenbaum, Liliane ^a,c  

^a ERASME HOSPITAL   (Belgium)

^b THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Confocal microscopy; GDNF; GFP; Hirt DNA; Immunohistochemistry; Intravenous injection; mRNA; Quantitative PCR; Retrograde transport; Stereotaxy

Indexed keywords

ADENO ASSOCIATED VIRUS; ANIMAL; ARTICLE; CENTRAL NERVOUS SYSTEM; CONFOCAL MICROSCOPY; GENE VECTOR; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; MOTONEURON; MOUSE; POLYMERASE CHAIN REACTION;

ANIMALS; CENTRAL NERVOUS SYSTEM; DEPENDOVIRUS; GENETIC VECTORS; IMMUNOHISTOCHEMISTRY; MICE; MICROSCOPY, CONFOCAL; MOTOR NEURONS; POLYMERASE CHAIN REACTION;

EID: 83455225632     PISSN: 10643745     EISSN: 19406029     Source Type: Book Series    
DOI: 10.1007/978-1-61779-370-7_7     Document Type: Chapter

References (33)

1. Ciron C, Desmaris N, Colle MA, Raoul S, Joussemet B, Verot L, et al. (2006) Gene therapy of the brain in the dog model of Hurler’s syndrome. Ann Neurol 60, 204–213.
2. Cachon-Gonzalez MB, Wang SZ, Lynch A, Ziegler R, Cheng SH, Cox TM. (2006) Effective gene therapy in an authentic model of Tay-Sachs-related diseases. Proc Natl Acad Sci USA 103, 10373–8.
3. Dodge JC, Clarke J, Song A, Bu J, Yang W, Taksir TV, et al. (2005) Gene transfer of human acid sphingomyelinase corrects neuropathology and motor deficits in a mouse model of Niemann-Pick type A disease. Proc Natl Acad Sci USA 102, 17822–7.
4. Fu H, Samulski RJ, McCown TJ, Picornell YJ, Fletcher D, Muenzer J. (2002) Neurological correction of lysosomal storage in a mucopolysaccharidosis IIIB mouse model by adeno-associated virus-mediated gene delivery. Mol Ther 5, 42–49.
5. Liu G, Chen YH, He X, Martins I, Heth JA, Chiorini JA, et al. (2007) Adeno-associated virus type 5 reduces learning deficits and restores glutamate receptor subunit levels in MPS VII mice CNS. Mol Ther 15, 242–7.
6. Kirik D, Rosenblad C, Bjorklund A, Mandel RJ. Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson’s model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigros-triatal system. J Neurosci 2000 Jun 15;20(12): 4686–4700.
7. Mandel RJ, Spratt SK, Snyder RO, Leff SE. (1997) Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson’s disease in rats. Proc Natl Acad Sci USA 94, 14083–8.
8. Yang X, Mertens B, Lehtonen E, Vercammen L, Bockstael O, Chtarto A, et al. (2009) Reversible neurochemical changes mediated by delayed intrastriatal glial cell line-derived neurotrophic factor gene delivery in a partial Parkinson’s disease rat model. J Gene Med 11, 899–912.
9. Kells AP, Henry RA, Connor B. (2008) AAV-BDNF mediated attenuation of quinolinic acid-induced neuropathology and motor function impairment. Gene Ther 15, 966–977.
10. Luo J, Kaplitt MG, Fitzsimons HL, Zuzga DS, Liu Y, Oshinsky ML, et al. (2002) Subthalamic GAD gene therapy in a Parkinson’s disease rat model. Science 298, 425–9.
11. Haberman RP, Samulski RJ, McCown TJ. (2003) Attenuation of seizures and neuronal death by adeno-associated virus vector galanin expression and secretion. Nat Med 9, 1076–80.
12. Shen Y, Muramatsu SI, Ikeguchi K, Fujimoto KI, Fan DS, Ogawa M, et al. (2000) Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson’s disease. Hum Gene Ther 11, 1509–19.
13. Carlsson T, Winkler C, Burger C, Muzyczka N, Mandel RJ, Cenci A, et al. Reversal of dyskine-sias in an animal model of Parkinson’s disease by continuous L-DOPA delivery using rAAV vectors. (2005) Brain 128, 559–69.
14. Xia H, Mao Q, Eliason SL, Harper SQ, Martins IH, Orr HT, et al. (2004) RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med 10, 816–20.
15. Rodriguez-Lebron E, Denovan-Wright EM, Nash K, Lewin AS, Mandel RJ. (2005) Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington’s disease transgenic mice. Mol Ther 12, 618–33.
16. Johnston LC, Su X, Maguire-Zeiss K, Horovitz K, Ankoudinova I, Guschin D, et al. (2008) Human interleukin-10 gene transfer is protective in a rat model of Parkinson’s disease. Mol Ther 16, 1392–9.
17. Yin D, Forsayeth J, Bankiewicz KS. (2009) Optimized cannula design and placement for convection-enhanced delivery in rat striatum. J Neurosci Methods 187, 46–51.
18. Mastakov MY, Baer K, Kotin RM, During MJ. (2002) Recombinant adeno-associated virus serotypes 2-and 5-mediated gene transfer in the mammalian brain: quantitative analysis of heparin co-infusion. Mol Ther 5, 371–380.
19. Mastakov MY, Baer K, Xu R, Fitzsimons H, During MJ. (2001) Combined injection of rAAV with mannitol enhances gene expression in the rat brain. Mol Ther 3, 225–232.
20. Paxinos, G. and Watson, 1997. “The rat brain in stereotaxic coordinates”, 3rd compact edition, Academic Press, Orlando, FLA
21. Paxinos, G. and Franklin, K.B.J., 1997. “The mouse brain in stereotaxic coordinates” 2nd edition, Academic Press
22. Peden CS, Burger C, Muzyczka N, Mandel RJ. (2004) Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain. J Virol 78, 6344–59.
23. Peden CS, Manfredsson FP, Reimsnider SK, Poirier AE, Burger C, Muzyczka N, et al. (2009) Striatal readministration of rAAV vectors reveals an immune response against AAV2 capsids that can be circumvented. Mol Ther 17, 524–537.
24. Duque S, Joussemet B, Riviere C, Marais T, Dubreil L, Douar AM, et al. (2009) Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther 17, 1187–96.
25. Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK. (2009) Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 27, 59–65.
26. Saunders NR, Joakim EC, Dziegielewska KM. (2009) The neonatal blood-brain barrier is functionally effective, and immaturity does not explain differential targeting of AAV9. Nat Biotechnol 27, 804–5.
27. Towne C, Schneider BL, Kieran D, Redmond DE, Jr., Aebischer P. (2010) Efficient transduction of non-human primate motor neurons after intramuscular delivery of recombinant AAV serotype 6. Gene Ther 17, 141–6.
28. Kaspar BK, Llado J, Sherkat N, Rothstein JD, Gage FH. (2003) Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 301, 839–842.
29. Zheng H, Qiao C, Wang CH, Li J, Li J, Yuan Z, et al. (2010) Efficient retrograde transport of adeno-associated virus type 8 to spinal cord and dorsal root ganglion after vector delivery in muscle. Hum Gene Ther 21, 87–97.
30. Hollis ER, Kadoya K, Hirsch M, Samulski RJ, Tuszynski MH. (2008) Efficient retrograde neuronal transduction utilizing self-complementary AAV1. Mol Ther 16, 296–301.
31. Sterio DC. (1984) The unbiased estimation of number and sizes of arbitrary particles using the disector. J Microsc 134, 127–36.
32. Hirt B. (1967) Selective extraction of polyoma DNA from infected mouse cell cultures. J Mol Biol 26: 365–9.
33. Okragly AJ, Haak-Frendscho M. (1997) An acid-treatment method for the enhanced detection of GDNF in biological samples. Exp Neurol 145, 592–6.